CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2016--
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced it will present at the
Goldman Sachs 37th Annual Global Healthcare Conference in
Rancho Palos Verdes, CA on Tuesday, June 7 at 9:20 a.m. PT.
Live audio webcast will be available under the Investors and Media
section of Seres’ website. A replay of the presentation will become
available approximately one hour after the event and will be archived
for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ most advanced program, SER-109, has successfully
completed a Phase 1b/2 study demonstrating a clinical benefit in
patients with recurring Clostridium difficile infection (CDI) and
is currently being evaluated in a Phase 2 study in recurring CDI. The
FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy,
designations. Seres’ second clinical candidate, SER-287, is being
evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis (UC). For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005694/en/
Source: Seres Therapeutics
IR and PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
Ctanzi@serestherapeutics.com
